Cargando…
Pharmacological modulation of ferroptosis as a therapeutic target for liver fibrosis
Liver fibrosis, which is characterized by the excessive deposition of extracellular matrix (ECM) materials (primarily fibrillar collagen-I), is an abnormal repair reaction and pathological outcome of chronic liver diseases caused by alcohol abuse, non-alcoholic fatty liver disease, and chronic hepat...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871257/ https://www.ncbi.nlm.nih.gov/pubmed/36703745 http://dx.doi.org/10.3389/fphar.2022.1071844 |
_version_ | 1784877128629616640 |
---|---|
author | Li, Le Zhu, Zhijun |
author_facet | Li, Le Zhu, Zhijun |
author_sort | Li, Le |
collection | PubMed |
description | Liver fibrosis, which is characterized by the excessive deposition of extracellular matrix (ECM) materials (primarily fibrillar collagen-I), is an abnormal repair reaction and pathological outcome of chronic liver diseases caused by alcohol abuse, non-alcoholic fatty liver disease, and chronic hepatitis B and C virus infections. Liver fibrosis often progresses to liver cirrhosis and hepatocellular carcinoma. Ferroptosis, characterized by lipid peroxidation, is a form of iron-dependent non-apoptotic cell death, and recent studies have reported that ferroptosis contribute to the development of liver fibrosis. Moreover, several agents have demonstrated therapeutic effects in experimental liver fibrosis models by inducing hepatic stellate cell (HSCs) ferroptosis. This review delineates the specific mechanism by which ferroptosis contributes to the development of liver fibrosis. Specifically, we focused on the different types of therapeutic agents that can induce HSCs ferroptosis and summarize their pharmacological effectiveness for liver fibrosis treatment. We suggest that HSCs ferroptosis may be a potential useful target of novel therapies for preventing and treating liver fibrosis. |
format | Online Article Text |
id | pubmed-9871257 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98712572023-01-25 Pharmacological modulation of ferroptosis as a therapeutic target for liver fibrosis Li, Le Zhu, Zhijun Front Pharmacol Pharmacology Liver fibrosis, which is characterized by the excessive deposition of extracellular matrix (ECM) materials (primarily fibrillar collagen-I), is an abnormal repair reaction and pathological outcome of chronic liver diseases caused by alcohol abuse, non-alcoholic fatty liver disease, and chronic hepatitis B and C virus infections. Liver fibrosis often progresses to liver cirrhosis and hepatocellular carcinoma. Ferroptosis, characterized by lipid peroxidation, is a form of iron-dependent non-apoptotic cell death, and recent studies have reported that ferroptosis contribute to the development of liver fibrosis. Moreover, several agents have demonstrated therapeutic effects in experimental liver fibrosis models by inducing hepatic stellate cell (HSCs) ferroptosis. This review delineates the specific mechanism by which ferroptosis contributes to the development of liver fibrosis. Specifically, we focused on the different types of therapeutic agents that can induce HSCs ferroptosis and summarize their pharmacological effectiveness for liver fibrosis treatment. We suggest that HSCs ferroptosis may be a potential useful target of novel therapies for preventing and treating liver fibrosis. Frontiers Media S.A. 2023-01-10 /pmc/articles/PMC9871257/ /pubmed/36703745 http://dx.doi.org/10.3389/fphar.2022.1071844 Text en Copyright © 2023 Li and Zhu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Li, Le Zhu, Zhijun Pharmacological modulation of ferroptosis as a therapeutic target for liver fibrosis |
title | Pharmacological modulation of ferroptosis as a therapeutic target for liver fibrosis |
title_full | Pharmacological modulation of ferroptosis as a therapeutic target for liver fibrosis |
title_fullStr | Pharmacological modulation of ferroptosis as a therapeutic target for liver fibrosis |
title_full_unstemmed | Pharmacological modulation of ferroptosis as a therapeutic target for liver fibrosis |
title_short | Pharmacological modulation of ferroptosis as a therapeutic target for liver fibrosis |
title_sort | pharmacological modulation of ferroptosis as a therapeutic target for liver fibrosis |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871257/ https://www.ncbi.nlm.nih.gov/pubmed/36703745 http://dx.doi.org/10.3389/fphar.2022.1071844 |
work_keys_str_mv | AT lile pharmacologicalmodulationofferroptosisasatherapeutictargetforliverfibrosis AT zhuzhijun pharmacologicalmodulationofferroptosisasatherapeutictargetforliverfibrosis |